Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3R2 | O00459 | 8/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 7/20 | 0.37 |
| ▸ | IDH2 | P48735 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19686414 | 0.89 | PIK3R2 (0.40) | PIK3R2IRAK4PIK3CAHRH4CYP1A1 | |
| SCHEMBL21165913 | 0.89 | IDH1 (0.35) | PIK3R2IDH1IDH2HRH4 | |
| SCHEMBL19687111 | 0.88 | HRH4 (0.34) | PIK3R2IDH1IDH2HRH4 | |
| SCHEMBL21165847 | 0.87 | IDH1 (0.36) | PIK3R2IRAK4IDH1IDH2HRH4 | |
| SCHEMBL21144306 | 0.86 | PIK3CA (0.46) | PIK3R2IRAK4PIK3CA | |
| SCHEMBL19686416 | 0.85 | IDH1 (0.37) | IRAK4IDH1IDH2HRH4 | |
| SCHEMBL21165919 | 0.84 | SYK (0.36) | IRAK4IDH1IDH2HRH4 | |
| SCHEMBL19686419 | 0.84 | IDH1 (0.37) | IDH1IDH2HRH4 | |
| SCHEMBL19686418 | 0.83 | IRAK4 (0.38) | PIK3R2IRAK4PIK3CAHRH4CYP1A1 | |
| SCHEMBL19686356 | 0.83 | RAF1 (0.44) | PIK3R2IRAK4IDH1IDH2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | PIK3R2 2034/4885IRAK4 1952/4885IDH1 3017/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | PIK3R2 2034/4885IRAK4 1952/4885IDH1 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.